In this episode, we sit down with Alexander Hardy, President and CEO of BioMarin, to talk about his path to leading one of the world's premier rare disease companies. Alexander reflects on his experience across small molecules, biologics, oncology, and rare diseases, and how his work in access and patient services has shaped his thinking about leadership. We discuss the policy environment coming out of Washington — including the IRA and other pricing reforms — and how those factors influence long-term innovation and investment decisions. We also explore the real-world challenges facing rare disease patients, employer concerns about high-cost therapies, and what needs to change over the next five years to improve access and affordability.
- Alexander Hardy
- PathoGenesis
- Eli Lilly | GSK | Novartis
- Genentech — Access Solutions
- BioMarin — Rare Connections
- AUTHrd Act of 2026 (part of the EPIC Act, HR 1492/S832) — pending before Congress
- Health Technology Assessments in Rare Diseases
Questions or comments? Email [email protected]. Find us on X, LinkedIn, YouTube, and Threads.